계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
Bright Angel Therapeutics
company
About
Bright Angel Therapeutics is developing new drugs that can prevent or revert the emergence of antifungal resistance.
- 1 - 10
Highlights
Details
- Last Funding Type
- Seed
- Industries
- Biotechnology
- Founded date
- Jan 1, 2016
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Bright Angel Therapeutics is a developer of novel therapeutics designed to provide treatment of drug-resistant and life-threatening fungal infections. The company's services increases efficacy of current treatments and eradicates drug resistance by targeting the stress responses required by fungi for survival, virulence and drug resistance, enabling users to overcome the frequent emergence of clinical resistance largely responsible for the severe morbidity and mortality associated with infection by diverse fungal pathogens.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
—
Bright Angel Therapeutics has raised a total of
—
in funding over 2 rounds. Their latest funding was raised on
Dec 3, 2019 from a Seed round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 3, 2019 | Seed | — | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Bright Angel Therapeutics is funded by 1 investors.
Schrödinger
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Schrödinger
|
— | Seed |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
